• First-in-Human ventricular ablation guided by real-time iCMR successfully performed
• Commenced VISABL-VT clinical trial and expanded VT site recruitment
• Received CE mark approvals for Advantage-MR system and NorthStar 3D mapping system

Imricor Medical Systems, Inc. (ASX: IMR) released its Appendix 4C Quarterly Cash Flow Report for the period ended 30 June 2025 and provided an update on its operational performance. Key highlights include:Regulatory:- First-in-Human ventricular ablation guided by real-time iCMR was successfully performed at Amsterdam University Medical Centre (AUMC)- Commenced VISABL-VT clinical trial- Additional VT site recruitment well progressed- Received CE mark approval for the Advantage-MR system under the new European Medical Device Regulation (MDR), following the CE mark approval of the Company's 2nd generation Vision-MR Ablation Catheter in Q1 2025- Received CE mark approval for NorthStar, the world's only MRI native 3D mapping and guidance system- Several US hospitals identified with existing MRI scanners in cardiology that are interested in joining the VISABL-AFL clinical trialCommercial:- Semmelweis University becomes the first hospital in Hungary to perform ablations guided by real-time iCMR- European sales team fully staffed with 6 field reps, up from 2 in the prior comparative period- Pipeline almost doubled from 14 to 27 vs Q1, with various sites progressing towards closing in the second half of calendar year 2025Financial:- Cash receipts of $85k temporarily impacted by customer sites enrolling VISABL-AFL patients, which are non-revenue generating in the short term- Operating cash outflows in Q2 of US$4.4m well contained and down 4% vs Q1- Cash balance of US$50.3m vs US$53.9m as at 31 March 2025- 11.4 quarters of funding on Q2 cash outflow

The company expects a steady string of 510(k) product submissions and approvals throughout the balance of 2025, which in turn helps accelerate the commercial launch across the United States.

Imricor is preparing for the launch of its 2nd generation devices and NorthStar across Europe, and expects an acceleration of hospital adoption into the end of 2025 and beyond as the final integrations with the Philips platform are completed.